Transcenta Holding Limited (Transcenta) will sell its contract development and manufacturing organisation (CDMO) assets to WuXi Biologics (Hangzhou) Co., Ltd., a wholly-owned arm of WuXi Biologics, for up to RMB190.00 million, according to a circular released on 25 August 2026.

The transaction, classified as a major disposal under Hong Kong’s Listing Rules, covers: • Land-use rights and building ownership of a 10,834.52 sq m GMP plant at No. 291 Fucheng Road, Qiantang New District, Hangzhou; • 1,202 sets of production facilities and 460 units of electronic and other equipment; • Ancillary structures and designated contracts and inventories; • Transfer of certain staff, with WuXi Biologics bearing up to RMB3.97 million of related compensation.

Payment terms: 1) First tranche: RMB95.00 million within five business days after shareholder approval; 2) Second tranche: RMB28.50 million upon Phase I completion; 3) Third tranche: RMB38.00 million upon Phase II completion; 4) Final tranche: RMB28.50 million within six months after Phase II completion. Both the second and final payments may be reduced if asset scope or value is lower than agreed.

Financial impact: • Carrying amount of the CDMO assets as at 30 June 2026: approximately RMB457 million, including RMB202 million goodwill. • Estimated disposal loss: about RMB280 million, to be recognised on Phase II completion. • The CDMO unit recorded unaudited net losses of RMB75.39 million in 2024 and RMB58.26 million in 2025 on revenue of RMB9.02 million and RMB6.38 million, respectively.

Net proceeds after expenses are projected at roughly RMB187.20 million, earmarked 50 % for lead programmes Osemitamab (TST001) and Blosozumab (TST002), 20 % for other pipeline assets and 30 % for working capital, with full deployment expected by end-2027.

Transcenta stated the sale will strengthen its cash position, streamline operating costs and allow management to focus on its core antibody drug R&D and technology-licensing businesses. The company expects meaningful reductions in depreciation and operating expenses following completion.

An extraordinary general meeting is scheduled for 9 September 2026 at 10:00 a.m. in Suzhou. The shareholder register will close from 4–9 September 2026 and proxies must be lodged by 7 September 2026. Completion of the deal is targeted by year-end 2026, subject to all conditions precedent being met.